You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 10, October 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Deep Brain Stimulation
 •Movement Disorders
 •Parkinson Disease/ Parkinsonian Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Pallidal vs Subthalamic Deep Brain Stimulation for Parkinson Disease: Winner and Loser or a Sharing of Honors?—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We read with interest the comments from Drs Minguez-Castellanos and Escamilla-Sevilla regarding dyskinesia threshold among patients participating in their open-label comparison study of pallidal and subthalamic DBS for Parkinson disease,1 in which they found presurgical levodopa dose to be the major predictor of postsurgical motor efficacy. In our study, we found no association of presurgical levodopa dose and improved motor efficacy (Unified Parkinson’s Disease Rating Scale motor or 24-point dyskinesia score) after 12 months of DBS.2 However, we also noted no significant differences in presurgical levodopa dose between the 2 groups, a factor that the letter’s authors correctly identify as a potential confounder. We agree with the authors that larger, randomized studies will be required to detect the important predictors of motor efficacy for a given surgical target. We further believe that measures of the nonmotor effects of DBS and secondary medication adjustments will offer additional insights into . . . [Full Text of this Article]

AUTHOR INFORMATION

Penelope Hogarth, MD; Valerie Anderson, PhD; John Hammerstad, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.